SDHB and neoplasm: Current evaluation of the tumor progression potential of PCC/PGL is based on multifactorial risk assessments, including the presence of SDHB mutation, larger tumor size, extra-adrenal location, dopamine hypersecretion, and several histopathologic scoring systems (14, 15).